Gene-mediated enzyme prodrug therapy (GDEPT) seeks to increase the therapeutic index of anti-neoplastic agents by promoting selective activation of relatively nontoxic drug derivatives at sites of specific enzyme expression. Glucuronide prodrugs are attractive for GDEPT due to their low toxicity, bystander effect in the interstitial tumor space and the large range of possible glucuronide drug targets. In this study, we expressed human, murine and Esherichia coli b-glucuronidase on tumor cells and examined their in vitro and in vivo efficacy for the activation of glucuronide prodrugs of 9-aminocamptothecin and p-hydroxy aniline mustard. We show that (1) fusion of b-glucuronidase to the Ig-like C 2 -type and Ig-hinge-like domains of the B7-1 antigen followed by the B7-1 transmembrane domain anchored high levels of active murine and human b-glucuronidase on cells, (2) strong bystander killing of tumor cells was achieved in vitro by murine b-glucuronidase activation of prodrug, (3) potent in vivo anti-tumor activity was achieved by prodrug treatment of tumors that expressed murine b-glucuronidase and (4) the p-hydroxy aniline prodrug was more effective in vivo than the 9-aminocamptothecin prodrug. Our results demonstrate that surface expression of murine b-glucuronidase for activation of a glucuronide prodrug of p-hydroxy aniline mustard may be useful for more selective therapy of cancer.
Introduction
Although many anti-neoplastic agents have demonstrated utility in the clinic, drug-induced toxicity to non-cancerous tissues can prevent attainment of therapeutic drug concentrations at cancer cells and lead to premature termination of therapy before achieving complete remission. More selective anti-neoplastic agents could positively influence therapy by reducing the exposure of normal tissues to cytotoxic drugs. GDEPT seeks to increase the therapeutic index of anti-neoplastic agents by selective delivery or expression in cancer cells of a gene that encodes an enzyme that converts a relatively non-toxic prodrug into an anti-neoplastic agent. Preferential activation of prodrugs at transduced cancer cells generates high drug concentrations in tumors while minimizing drug exposure to normal tissues. 1 Several GDEPT systems have been developed for selective cancer treatment, the most prevalent being herpes simplex thymidine kinase activation of ganciclovir 2, 3 and Esherchia coli-derived cytosine deaminase activation of 5-fluorocytosine. 4 Phosphorylation of ganciclovir by herpes simplex thymidine kinase is followed by a series of intracellular reactions that produces a triphosphate that is trapped within the target cells. The triphosphate product can compete with deoxyguanosine triphosphate during DNA elongation, thereby inhibiting DNA polymerase and causing single-strand breaks. 5 Ganciclovir, however, is S-phase specific and kills only actively dividing cells, 6 a disadvantage in tumors containing regions of nonproliferating cells. Bystander killing by ganciclovir also relies on gap junctions for transport of the charged triphosphate to neighboring cells, which can limit the bystander effect in tumors since the expression of connexins is often decreased in neoplastic tissues and by hypoxia. 7 Furthermore, low concentrations of ganciclovir can also cause chromosome breaks and sister chromatid exchange. 8 Cytosine deaminase derived from some bacterial and fungal sources is capable of converting the less toxic 5-fluorocytosine to 5-FU. 5-fluouracil (5-FU) is enzymatically converted to 5-FUTP, which is incorporated into DNA and prevents nuclear processing of ribosomal and mRNA, and to 5-fluorouridine-5 0 -monophosphate, which irreversibly inhibits thymidylate synthase. 9 In contrast to ganciclovir, bystander killing by 5-FU is not dependent on gap junctions because this drug can diffuse into and out of cells. 10 5-FC, however, is relatively hydrophilic and therefore diffuses across the plasma membrane of cells slowly, but is rapidly excreted from some cells. 11 Furthermore, because the inherent sensitivity of tumor cells is an important factor in determining the efficacy of suicide gene therapy with 5-FC, 12 this prodrug is unsuitable for many tumor types. Although suicide gene therapy with either ganciclovir or 5-FC appears to safe, only marginal clinical efficacy has been observed, [13] [14] [15] [16] indicating the need for more efficacious GDEPT systems.
b-glucuronidase (bG) is attractive for GDEPT for several reasons. First, a wide variety of glucuronide prodrugs are available, including prodrugs of effective antineoplastic agents such as doxorubicin, 17, 18 etoposide, 19 camptothecin analogs, 20, 21 paclitaxel, 22 docetaxel 23 and alkylating agents. 24, 25 In fact, glucuronide derivatives of almost any anti-neoplastic agent can be synthesized by employing linkers between the drug and glucuronide moieties. 22, 23 This is a major advantage since the most effective prodrug can be selected for a particular tumor type. Second, glucuronide prodrugs do not readily enter cells due to their charged carboxy group, minimizing interactions with endogenous bG located inside lysosomes. 17 Thus, prodrug activation selectively occurs at sites of exogenous bG expression only if the enzyme is located extracellularly. 26 Surface expression of prodrugactivating enzymes may promote more extensive killing of non-transduced cancer cells since activated drug is not trapped in the cytosol of transduced cells. For example, hydrolysis of glucuronide prodrugs by bG released from cells or targeted to the cell membrane produces potent cytotoxicity as well as bystander killing of neighboring enzyme-negative cells, [27] [28] [29] an important consideration given the low transduction efficiencies achievable in vivo. Finally, glucuronide prodrugs produce potent anti-tumor activity in antibody-directed enzyme prodrug therapy (ADEPT), in which specific antibodies are employed to deliver bG to cancer cells [30] [31] [32] as well as directly in prodrug monotherapy, which relies on the presence of elevated levels of bG in the tumor interstitial space. 33, 34 Although many variables may influence the effectiveness of GDEPT, we hypothesized that maximizing the activity of bG on tumor cells is of primary importance. In the present study, we examined the effectiveness of anchoring bG on cells with different juxtamembrane spacer domains and transmembrane domains ( Figure 1a) . As different sources of bG display unique kinetic properties, we compared the surface expression, surface activity, in vitro prodrug activation and in vivo anti-tumor activity of E. coli (ebG), murine (mbG), and human (hbG) bG. hbG has previously been expressed as a secreted or membrane anchored form for the selective activation of a glucuronide prodrug of doxorubicin, 28, 29 but other bG enzymes have not been examined. Finally, we directly compared the in vitro and in vivo efficacy of two glucuronide prodrugs, HAMG and 9ACG. HAMG is a glucuronide prodrug that can be enzymatically converted by bG to p-hydroxy aniline mustard (pHAM), a potent alkylating agent. 24, 35 We previously demonstrated that combined treatment with immunoenzymes and HAMG could cure late-stage malignant ascites 31 as well as cause the regression of human tumors in mice. 32, 36 9ACG is a water soluble prodrug that can be hydrolyzed by bG to release 9-aminocamptothecin (9AC), an anti-tumor alkaloid that inhibits topoisomerase I to produce selective anti-tumor activity. 37, 38 9ACG displays anti-tumor activity against human xenografts. 34 The active prodrug of 9ACG is about 1000 times more potent than the activated form of HAMG, suggesting that these prodrugs may display differences in their effectiveness.
Materials and methods

Reagents and antibodies
The synthesis of pHAM, HAMG, 9AC and 9ACG have been described. 20, 35 Rat anti-HA antibody was from Roche (Basel, Switzerland). Mouse anti-b-actin and rabbit anti-BiP were from Sigma Aldrich (St Louis, MO, USA). Horseradish peroxidase (HRP), FITC and rhodamine-conjugated secondary antibodies were from Jackson ImmunoResearch Laboratories (Westgrove, PA, USA) or Organon Teknika Corp (Durham, NC, USA). Monoclonal antibody 1E8 (IgG 1 against ebG) has been described. 39 To generate monoclonal antibodies (mAb) against hbG (1B3, IgG 1 and 7G8, IgG 2b ), female Balb/c mice were s.c. injected with 100 mg recombinant hbG in complete Freund's adjuvant, and then boosted at 3-4 week intervals with decreasing doses of hbG in incomplete adjuvant. At 3 days before fusion with FO myeloma cells, the mice were i.p. injected with 30 mg hbG in PBS. Hybridomas were screened by ELISA for clones secreting antibodies that bound hbG but not mbG or ebG. Stable hybridomas were obtained by repeated limiting dilution cloning. A rat mAb against mbG (7G7, IgG) was generated in an analogous fashion by immunizing Lou/c rats with recombinant mbG before splenocytes were fused with FO myeloma cells.
DNA constructs
The hbG cDNA fragment in pLNCX-hbG, 40 the mbG cDNA fragment in pLHCX-mbG 40 and the ebG fragment in pGUS N358S (Clontech, Mountain View, CA, USA) were inserted in place of the 2C11 scFv gene (SfiI/SalI fragment) in p2C11-PDGFR, p2C11-BGP-B7, p2C11-e-B7, p2C11-g 1 -B7 and p2C11-CD44-B7 41, 42 to create the corresponding transgenes for surface expression of hbG, mbG and ebG. Removal of the immunoglobulin hinge region in the g 1 domain of p-hbG-g1-B7 produced p-hbGmg 1 -B7. p-hbG-L-e-B7 includes cDNA for a 10 aminoacid linker (GGGGSGGGGS) at the 5 0 -end of the e-B7 domain. p-hbG-ICAM was generated by inserting the hbG cDNA fragment between the ICAM-1 leader sequence and ICAM-1 transmembrane domain in pLTM-1 (generously provided by Dr Alister Craig, University of Oxford, UK). Insertion of the hbG-e-B7, mbG-e-B7 and ebG-e-B7 transgenes into the retroviral vector pLNCX (BD Biosciences, San Diego, CA, USA) generated the retroviral vectors pLNCX-hbG-e-B7, pLNCX-mbG-e-B7 and pLNCX-ebG-e-B7. pNeo/GUS and pLS/GUS, which direct the expression of ebG to the cytosol or allow secretion of ebG, respectively, have been described. 26 Expression of all transgenes was under control of the CMV promoter.
Cell lines
Balb/3T3 fibroblasts (CCL-163) and CT26 murine colon carcinoma cells (CRL-2638) were grown in DMEM (high glucose) supplemented with 10% bovine serum, 2.98 g/l HEPES, 2 g/l NaHCO 3 , 100 U/ml penicillin and 100 mg/ml streptomycin. EJ human bladder carcinoma cells 43 were cultured in RPMI containing the same Figure 1 bG activation of glucuronide prodrugs. (a) bG is anchored on cancer cells via a spacer domain fused to a TM. The glucuronide prodrugs HAMG or 9ACG can be enzymatically converted by bG to the anti-neoplastic agents pHAM or 9AC, respectively. (b) General layout of the transgenes for surface expression of bG. The transgenes code for the immunoglobulin kappa chain leader sequence (kLS) followed by an HA epitope (HA) and the mature bG gene. Sequences coding 'spacer' domains (BGP, g1, mg1,e, L10-e and CD44) were derived from cell receptors as described in the text. Black bars indicate the presence of N-linked glycosylation sites. TM were derived from human ICAM-1, the human platelet-derived growth factor receptor or the mouse B7-1 antigen.
supplements. The cells were free of mycoplasma as determined by PCR.
Transfection of bG transgenes 3T3 fibroblasts were transfected with plasmid DNA using Lipofectamine 2000 (Gibco Laboratories, Grand Island, NY, USA). To generate stable cell lines, pLNCX-ebG-e-B7, pLNCX-hbG-e-B7 and pLNCX-mbG-e-B7 were co-transfected with pVSVG in GP293 cells (Clontech) to produce recombinant retroviral particles. At 2 days after transfection, the culture medium was filtered, mixed with 8 mg/ml polybrene and added to EJ or CT26 cells. Stable cell lines were selected in medium containing G418.
Western blot analysis
Transiently transfected 3T3 fibroblasts were boiled in reducing SDS buffer, electrophoresed on a SDS-PAGE and transferred to PVDF membranes. Membranes were sequentially probed with anti-HA antibody or mAb 1B3 against hbG followed by HRP-conjugated secondary antibody. The membranes were stripped and reprobed with anti-b-actin antibody. Bands were visualized by ECL detection (Pierce, Rockford, IL, USA). Relative expression levels of bG were normalized to b-actin band intensities using the shareware program NIH Image (http://rsb.info.nih.gov/nih-image/download.html).
Flow cytometer analysis
Cells were stained with anti-HA antibody followed by FITC-conjugated goat anti-rat F(ab') 2 fragment. Alternatively, cells were stained with mAb 1E8 against ebG, 39 mAb 7G8 against hbG or mAb 7G7 against mbG followed by the appropriate FITC-labeled secondary antibody. The surface immunofluorescence of 10 000 viable cells was measured with a FACScaliber flow cytometer (Becton Dickinson, Mountain View, CA, USA) and fluorescence intensities were analyzed with Flowjo V3.2 (Tree Star Inc., San Carlos, CA, USA).
Surface enzyme activity assay
Transiently transfected 3T3 fibroblasts in 96-well microplates were washed once with PBS and immediately assayed for bG activity by adding 200 ml PBS (pH 7.0) containing 0.1% BSA and 0.25 mM 4-methylumbelliferyl b-D-glucuronide for 30 min at 371C. 150 ml of the reaction mixture were transferred to a 96-well fluorescence microplate and mixed with 75 ml stop buffer (1 M glycine/0.5 M sodium bicarbonate, pH 11). The fluorescence of the wells was measured at an excitation wavelength of 365 nm and an emission wavelength of 455 nm.
Production and characterization of recombinant bG Recombinant ebG, mbG and hbG were produced as described. 36, 40 Enzymatic activities at defined pH values were measured in triplicate as described. 40 One unit bG activity corresponds to the hydrolysis of 1 mmole p-nitrophenol b-D-glucuronide per h at 371C.
H-thymidine incorporation assay
Graded concentrations of drugs were added in triplicate to cell lines at pH 6.6 or pH 7.4 for 24 h at 371C. The cells were incubated in fresh medium for 24 h and then pulsed for 16 h with and Mg 2 þ for 1 h at room temperature. The cells were cultured in complete medium for 24 h before the cells were immunofluorescence stained for the HA epitope and analyzed by flow cytometry.
Intracellular immunofluorescence staining
Cells on glass coverslips were fixed with 4% paraformaldehyde in PBS for 15 min and then permeabilized with 1% Triton X-l00 in PBS for 10 min. The cells were stained with biotin-labeled goat anti-HA and streptavidin-labeled rhodamine or rabbit anti-BiP and rhodamine-labeled goat anti-rabbit IgG, mounted on slides in 50% glycerol/PBS, and viewed under a digital fluorescence microscope.
Secretion of ebG from fibroblasts
The culture medium from transiently transfected 3T3 fibroblasts was collected after 48 or 60 h. The cells were suspended in 0.1% Triton X-100/PBS, freeze/thawed three times and centrifuged to remove insoluble material. Cell lysate and culture medium were assayed for bG activity at pH 7 for ebG and at pH 4.5 for mbG and hbG.
The measured activities were adjusted to calculate the bG activity originally present in the total cell and medium fractions.
Statistical significance
Statistical significance of differences between mean values was estimated with Excel (Microsoft, Redmond, WA, USA) using the independent t-test for unequal variances. P-values of o0.05 were considered statistically significant.
Results
Transmembrane and spacer domains can influence bG surface expression
Previous studies have demonstrated that the transmembrane domain (TM) and the juxtamembrane 'spacer' domain employed to anchor single-chain antibodies (scFv) on the plasma membrane of cells can greatly affect cell surface expression levels. 41, 42, 44 To examine whether the expression of hbG on cells also depended on the TM and spacer domains, a panel of hbG transgenes was constructed with an immunoglobulin k chain signal sequence and an HA tag at the 3 0 end of the mature hbG cDNA (Figure 1b) . TM from the human platelet-derived growth factor receptor (PDGFR), the murine B7-1 antigen (B7) or human intracellular adhesion molecule 1 (ICAM-1) were employed to anchor hbG on the cell surface. The PDGFR TM includes six amino acids of the cytoplasmic tail whereas the B7 TM includes the entire 38 amino acid cytoplasmic tail of the B7-1 antigen. Spacer domains introduced between hbG and the B7 TM included the first immunoglobulin-like V-type domain of human biliary glycoprotein I (hbG-BGP-B7), the Ig-like C2-type and Ig-hinge-like domains of the murine B7-1 antigen (hbG-e-B7), the hinge-CH 2 -CH 3 domains of human IgG 1 (hbG-g 1 -B7), the CH 2 -CH 3 domains of human IgG 1 (hbG-mg 1 -B7) and the extracellular portion of human CD44E (hbG-CD44-B7). The g 1 domain allows formation of disulfide linked dimers. 41 A sequence coding a 10 amino acid flexible linker (GGGGSGGGGS) was appended to the 3 0 end of hbG in hbG-L-e-B7 to examine the influence of additional flexibility between the domains.
We transiently transfected the hbG transgenes into murine 3T3 fibroblasts and detected the protein products by immunoblotting whole cell lysates with an antibody against the HA epitope in the chimeric proteins. The transfected fibroblasts expressed the chimeric proteins at similar levels (Figure 2a) . hbG-ICAM does not contain the HA epitope but was detected with anti-hbG antiserum (Figure 2b ). Immunofluorescence staining of transiently transfected fibroblasts showed that cells poorly expressed hbG-ICAM, moderately expressed hbG-PDGFR and highly expressed hbG-BGP-B7, hbG-e-B7 and hbG-CD44-B7 (Figure 2c ). Repeated transient transfection experiments showed that hbG-e-B7 and hbG-L-e-B7 directed the highest expression of hbG on the cells (Figure 2d, open bars) . hbG-e-B7 and hbG-L-e-B7 also displayed the greatest bG enzyme activity on the cells (Figure 2d, solid bars) . phOx-e-B7, a scFv that is highly expressed on cells, was included to demonstrate the specificity of the anti-hbG antibody and enzyme activity assays. Comparison of mbG expression on fibroblasts showed that mbG-e-B7 and mbG-CD44-B7 directed about twice the amount of mbG to the cell surface as compared with mbG-BGP-B7 (Figure 2e) . Although the expression of ebG was low regardless of the spacer used, bG-CD44-B7 allowed the expression of about twice the levels of ebG on the cell surface as compared to ebG-eB7 (Figure 2f) . The enzymatic activity of ebG-CD44-B7, however, was dramatically lower than ebG-e-B7, indicating that the CD44 spacer did not allow proper folding or formation of the ebG tetramer. Taken together, our results demonstrate that the B7-1 spacer and the B7 TM anchored the highest levels of active bG on cells.
Stable expression of mbG, hbG and ebG on EJ carcinoma cells Retroviral transduction of EJ human bladder cancer cells generated stable EJ transfectants that expressed hbG-e-B7, mbG-e-B7 or ebG-e-B7 (EJ/hbG, EJ/mbG and EJ/ebG cells, respectively). Immunoblotting of whole cell lysates demonstrated that hbG-e-B7 and mbG-e-B7 were expressed at about 2.5-fold higher levels as compared to ebG-e-B7 (Figure 3a) . Large amounts of both hbG-e-B7 and mbG-e-B7 were detected on the surface of live EJ transfectants, but ebG-e-B7 levels on the plasma membrane were about 20-fold lower (Figure 3b ). Murine fibroblasts (Figure 2c ) and murine colon carcinoma CT26 cells displayed similar large differences in the surface levels of hbG and mbG versus ebG (results not shown). Both hbG-e-B7 and mbG-e-B7 were easily visualized on the plasma membrane of cells whereas ebG-e-B7 was only weakly detected (Figure 3c ). EJ/mbG cells displayed two-to threefold more bG activity than did EJ/ebG cells and fivefold higher activity than EJ/hbG cells ( Figure 3d ). As expected, EJ cells did not hydrolyze the glucuronide substrate.
The neutral pH optimum of ebG or a high specific enzyme activity could cause the relatively effective hydrolysis of glucuronide substrates by the low levels of ebG present on EJ/ebG cells. To differentiate these possibilities, we produced and purified recombinant forms of each enzyme to measure accurately their specific activities at defined pH values ( Figure 3e ). As expected, ebG displayed optimal catalytic activity at neutral pH whereas both hbG and mbG exhibited maximal activities at pH 4-4.5 ( Figure 3f ). ebG displayed a maximal specific activity of 20 000 U/mg whereas hbG and mbG had maximal specific activities of 1600 and 1100 U/mg (Figure 3g) . Thus, ebG possesses intrinsically higher catalytic activity as compared to the lysosomal enzymes.
Membrane-localized prodrug activation
The proliferation of the EJ cell lines after treatment with drugs showed that all the cell lines were similarly sensitive to 9AC with IC 50 values ranging from 5 to 9 nM ( Figure 4a ). As expected, EJ cells were relatively (Figure 6c ). As the interstitial space of tumors is often acidic, 45 we examined the cytotoxicity of HAMG to cells at pH 6.6. Figure 6d shows that HAMG was about 80-fold more toxic to CT26/mbG cells (IC 50 ¼ 2.8 mM) than to CT26 cells (IC 50 ¼ 220 mM), demonstrating relatively efficient activation of HAMG by CT26/mbG cells at slightly acidic pH values. As it is difficult to transduce all the cancer cells in a tumor, we also investigated whether activation of HAMG could produce bystander killing of parental CT26 cells. Addition of HAMG to as few as 5% CT26/ mbG cells mixed with 95% CT26 cells significantly reduced 3 H-thymidine incorporation as compared to prodrug treatment of CT26 cells (Figure 6e) , showing that surface activation of HAMG produces potent bystander killing. The in vivo anti-tumor activity of HAMG was examined in a mouse subcutaneous tumor model. HAMG also displayed potent anti-tumor activity to established CT26/mbG tumors with two of six mice experiencing complete tumor rejection (Figure 6f ). As expected, HAMG did not display anti-tumor activity against CT26 tumors. The therapy was well tolerated with a transient weight loss of 12% in the CT26/mbG group treated with HAMG as compared to a 5% weight loss observed in the CT26/mbG group treated with PBS.
Mammalian cells can secrete ebG
The poor expression of ebG-e-B7 on the surface of various cells suggested that cells retained ebG. Both hbGe-B7 and mbG-e-B7 displayed similar intracellular distributions with typical golgi localization whereas ebG-e-B7 was more diffusely present in EJ/ebG cells (Figure 7a) . Staining for BIP, a resident ER protein, demonstrated colocalization of BIP and ebG-e-B7 (Figure 7b) , indicating a predominantly ER localization. By contrast, most mbG-e-B7 did not colocalize with BIP (Figure 7c) .
To determine if the ER retention of ebG-e-B7 was an inherent property of ebG, murine fibroblasts were transfected with pLS/GUS or pNeo/GUS (Figure 7d ) to allow for secretion or cytosolic expression of ebG, respectively. Cells transfected with pLS/GUS secreted about three-fourths of ebG, showing that ebG can be efficiently secreted from mammalian cells (Figure 7e ). By contrast, ebG was largely associated with the cell fraction in cells infected with pNeo/GUS. The total activity of ebG was similar in cells transfected with pLS/GUS or pNeo/ GUS, demonstrating that the activity of ebG was retained through the secretory pathway. Thus, retention of ebG-e-B7 in cells is not an inherent property of ebG. Control cells transfected with pLNCX-mbG or pLNCX-hbG displayed equal distribution of bG activity in the medium and cell fraction.
We also examined the possibility that the low expression of ebG-e-B7 was due to rapid shedding of the enzyme from the cell surface. Measurement of bG activities in the culture medium and cell fraction, however, showed that ebG-e-B7 was associated with cells as efficiently as were mbG-e-B7 and hbG-e-B7 (Figure 7f ). The total activity of cells transfected with pLNCX-ebG-e-B7 (4.8 U), however, was much lower than the activity of cells transfected with pLS/GUS or pNeo/GUS (600 and 570 U, respectively), indicating loss of ebG catalytic activity in ebG-e-B7.
Discussion
Expression of bG on cancer cells to preferentially activate glucuronide prodrugs is attractive for GDEPT because a wide range of glucuronide prodrugs have been synthesized, glucuronide prodrugs typically display orders of magnitude less toxicity as compared to the activated product, 17, 20, 24 potent bystander killing of cancer cells may be achieved, 27 and the same gene can potentially be employed for gene expression imaging and therapy. 46 In the present study, we show that maximizing bG activity on cancer cells dramatically enhanced in vivo anti-tumor efficacy. We also found that the glucuronide prodrug HAMG was superior to 9ACG for GDEPT.
We anchored bG on the surface of cells by fusion of the enzyme to type I TM. Spacer domains between bG and the TM allow more flexible assembly of bG tetramers and contain glycosylation sites that reduce the shedding of chimeric proteins, 42 presumably by hindering proteolytic cleavage of the receptors. The hbG-e-B7 construct allowed the highest expression of active hbG on fibroblasts. This construct also allowed most effective expression of active mbG and ebG on cells. An analogous chimeric receptor directed the highest levels of a singlechain antibody (scFv) on cells. 42 In contrast to scFv, however, the expression of hbG on cells was relatively insensitive to the nature of the TM and the presence of a spacer domain. For example, attachment of the B7 TM to a scFv resulted in a 15-fold increase in the level of scFv on the cell surface as compared to attachment of the PDGFR TM. 47 Likewise, introduction of the e-B7 spacer between the scFv and B7 TM further increased surface expression by about eightfold. 42 In contrast, the expression of hbG-e-B7 on cells was only about 2.5-fold higher than hbG-PDGFR. We attribute these differences to the bulky, tetrameric structure of bG. Accumulation of chimeric receptors on cells depends on their intracellular transport rate and half-life. scFv are highly susceptible to shedding 42 and surface expression can thus be greatly enhanced by the TM (which affects the rate of intracellular transport 44 ) and the spacer domain (which hinders shedding of the receptor 42 ). By contrast, the bulky structure of bG 48 likely hinders shedding as previously found for another large protein. 44 In addition, shedding of the enzyme requires cleavage of all four 'legs' of the bG tetramer. Stable surface expression allows accumulation of bG on cells even at relatively slow rates of intracellular transport. Thus, the choice of spacer and TM had less impact on the amount of hbG present on the cell surface.
Comparison of three different sources of bG revealed that mbG possessed the best combination of surface expression and activity for GDEPT. Thus, EJ/mbG cells exhibited greater bG activity, were significantly more sensitive to both 9ACG and HAMG and had growth significantly suppressed by two glucuronide prodrugs in vivo as compared to cells expressing hbG or ebG. Although cells expressed hbG and mbG at similar levels, (e) 3T3 fibroblasts were transiently transfected with the indicated vectors and the ratio of bG activity in the culture medium (secreted) relative to the bG activity in the total cell lysate (cellular) was determined 48 h later (n ¼ 3) (f) 3T3 fibroblasts were transiently transfected with the indicated vectors and the ratio of bG activity in the culture medium (secreted) relative to the bG activity in the total cell lysate (cellular) was determined 60 h later (n ¼ 3). ebG activity was measured at pH 7 whereas mbG and hbG activities were assayed at pH 4.5. The units of bG activity present in the culture medium and cell lysates (secreted/cellular) are shown above each bar. mbG displayed about three times greater enzymatic activity at pH 7. The K m of mbG is lower than hbG at pH 7 (results not shown), indicating that the effective activity differences between mbG and hbG may be even greater at low prodrug concentrations. Furthermore, the clear superiority of mbG as compared to hbG suggests that even modest increases in expression levels and specific catalytic activity can enhance therapeutic efficacy. Screening for more active bG variants from other species or development of bG mutants with higher enzyme activity appear to be warranted. ebG displayed optimal activity at physiological pH values and possesses higher intrinsic bG activity as compared to either lysosomal bG, but was poorly expressed on the plasma membrane. Furthermore, attachment of spacer or TM domains damaged ebG activity. This was most apparent with ebG-CD44-B7, which produced high surface expression but low bG activity. Immunofluorescence staining of EJ cell lines indicated that ebG was retained in the ER. As mbG can be retained in the ER by complex formation with egasyn, 49 we tested whether ebG retention was an intrinsic property of the bacterial enzyme. Murine fibroblasts, however, secreted ebG more efficiently than hbG or mbG. It thus appears that attachment of spacer or TM domains changed the conformation of ebG and hindered its transit from the ER. We also attempted to anchor ebG to cells by attachment of a type II TM (asialoglycoprotein receptor) with eB7, BGP or CD44 spacers to the N-terminus of ebG but surface expression levels were uniformly poor (results not shown). The mechanism of the low expression of ebG on the cell membrane requires additional investigation.
HAMG displayed better anti-tumor activity than 9ACG against EJ-mbG tumors; 9ACG significantly suppressed the growth of tumors but did not cause complete tumor regression whereas HAMG caused regression of all tumors and cured two mice of established tumors. This result was unexpected because the active form of 9ACG is about 1000 times more potent than the active form of HAMG. We speculate that HAMG may be more effective in vivo due to its rapid and uniform modes of action. Alkylating agents such as pHAM, the activated form of HAMG, cross-link DNA and act rapidly. For example, similar IC 50 values to pHAM are obtained after exposure to cells for 2 or 24 h. 32, 36 Furthermore, the cytotoxic effects of alkylating agents are relatively insensitive to the cell cycle status of cells. 50 By contrast, 9AC, the activation product of 9ACG, inhibits topoisomerase I and kills cells in a time-dependent fashion; short exposure to topoisomerase inhibitors is ineffective. 51 Glucuronide prodrugs that produce rapidly acting drug products may therefore be more favorable for GDEPT since glucuronides are rapidly eliminated from the circulation. 52 Mice also tolerated HAMG well. Bolus injections (i.v.) of up to 240 mg/kg HAMG did not produce weight loss in mice. Treatment of mice bearing CT-26/mbG tumors produced modest but transient weight loss. Although not investigated in the present study, we previously found that the normal doselimiting toxicity of alkylating agents, leukopenia, was greatly reduced in rats treated with a bG immunoconjugate and HAMG as compared to treatment with pHAM. 31 The short half-life of pHAM (on the order of minutes) 26 may help reduce systemic toxicity. A study showing that surface hbG activation of a doxorubicin prodrug produced anti-tumor activity in mice 29 suggests that multiple glucuronide prodrugs may be suitable for GDEPT with bG.
An advantage of GDEPT over ADEPT is the possibility of employing 'immunogenic' enzymes for therapy. In ADEPT, antibody-enzyme fusion proteins containing non-human enzymes induce neutralizing antibodies that curtail repeated treatment cycles. 53 Although tumors in mice lost expression of non-syngeneic bG (ebG and hbG), this may be less important for the transient expression required in clinical settings. For example, non-mammalian enzymes are commonly employed in GDEPT. 3, 54 This suggests that mbG-e-B7 could activate glucuronide prodrugs in humans.
In summary, linking bG to the Ig-like C 2 -type and Ighinge-like domains of the B7-1 antigen (e-B7) followed by the B7-1 TM allowed high-level expression of hbG and mbG on cells. HAMG was more effective than 9ACG for GDEPT and mbG-e-B7 achieved the best compromise between surface expression and catalytic activity. The high specific activity of ebG at physiologically relevant pH values (about 65-fold greater than mbG and 200-fold greater than hbG at pH 7) makes this enzyme highly attractive for GDEPT, but strategies are required to engineer surface forms of this enzyme that promote rapid intracellular transport with retention of enzymatic activity. Finally, we have recently shown that mbG-e-B7 can be employed to image gene expression in mice. 46 The same gene can therefore be employed to first verify successful and proper expression of the transgene in target tissue and then to activate glucuronide prodrugs for therapy.
